HUBS3403-Neuroscience

Running Head: LONGITUDINAL EVALUATION OF DTI (MRI) FOR RRMS MANAGING LONGITUDINAL EVALUATION OF DTI (MRI) ROLE FOR RRMS MODIFYING THERAPIES Name of the Student: Name of the University: Author Note: 1 LONGITUDINAL EVALUATION OF DTI (MRI) FOR RRMS MANAGING Introduction: Multiple sclerosis (MS) is a central nervous system (CNS) condition in which auto -aggressive immune cells activate, causing inflammation, demyelination, and axonal and synaptic dysfunction in both focal and diffuse areas (Dolati et al., 2018). Traditional magnetic resonance imaging (M RI) is highly sensitive in detecting white -matter focal inflammatory behaviour, as demonstrated by gadolinium (Gd) -enhancing T1 -weighted lesions or fresh T2 -weighted lesions (Zhang et al., 2016). MRI adjustments are frequently used as data sources in phase II and III studies of disease -modifying treatments (DMTs). Clinical studies with smaller study sizes and reduced timeframes will gain from MRI measures of regression prevention, such as a decline in Gd -enhancing T1 or the production of new/enlarging T2 le sions. Following the incorporation of imaging findings in the International Commission on the Diagnosis of Multiple Sclerosis' diagnostic recommendations, MRI has become profoundly significant in clinical practise (Thompson et al., 2018). According to the Expanded Disability Status Scale (EDSS), T2 lesion load is linked to medically certain MS and severe long -term damage in clinically isolated syndrome (CIS) (Guzel et al., 2016). The number of Gd -enhancing T1 lesions is related to further brain atrophy, whi ch is linked to the progression of disabilities (Radue et al., 2015). The association between T2 lesion volume and EDSS score change is strongest in the first 5 years of post diagnosis. In uncontrolled relapsing –remitting MS (RRMS) patients, the number of new/enlarging T2 fragments or the occurrence of Gd -enhancing T1 lesions is weakly associated with disease aggregation in the short term, but is more strongly correlated in the long term (Rocca, Comi & Filippi, 2017). The explanatory value of continuing MRI operation for long -term outcomes is greater in treated RRMS patients than in untreated RRMS patients. Rudick et al. (Göçmen, 2018) discovered that 2 LONGITUDINAL EVALUATION OF DTI (MRI) FOR RRMS MANAGING the amount of Gd -enhancing damages in patients on interferon -beta (IFN) -1a was a stronger predictor of EDSS growth than relapses. In the first year of IFN treatment, the formation of 1 Gd -enhancing T1 or new T2 lesions was linked to a significantly higher probability of relapses and EDSS progression (Dolati et al., 2015). According to Gasperini et al., patients with ongoing radiographic disease after one year of percutaneous IFN -1a therapy had a 50% risk of developing EDSS at four years (2019). In a specific meta -analysis of 40 CIS, RRMS, and secondary - progressive MS (SPMS) studies, researchers discovered a conne ction between T2 lesion parameters (percentage and density) in the first two years of treatment and EDSS progression (Burt et al., 2019). In relation to previous reports, this one included experimental trials of targeted agents such as fingolimod and dimet hyl fumarate (DMF) -Tecfidera, with the assumption that the strength of the association between T2 lesion indicators and EDSS score could differ based on the medication (Burt et al., 2019). The following paper explores the role of DTI in assessing multiple MS -altering therapies, as well as deciding the interaction between clinical parameters within the care timeline. Discussion: Monitoring disease activity in multiple sclerosis (MS) and assessment of MODIFYING THERPIES (Fingolimod and DMF -Tecfidera) for RRMS PATIENTS: While there have been significant advancements in the treatment of multiple sclerosis (MS) in recent years, with a growing amount of disease -modifying therapies (DMTs) being effective, the disease remains a highly hazardous and disabling problem because none of the new medications stops or cures the disease. A wide variety of neurological problems, along with vision, gait, and 3 LONGITUDINAL EVALUATION OF DTI (MRI) FOR RRMS MANAGING motor control, memory, flexibility, and equilibrium, as well as bladder, intestine, and sexual function, can be impaired (Vanbellingen & Kamm, 2016). Cognitive dysfunction, for example, is observed in up to 82 percent of MS patients; it can be identified early in the disease and has a detrimental effect on work, everyday lives, and social activity (Hynicová et al., 2017). Fu rthermore, MS induces progressive dysfunction in the majority of cases, and may affect both motor and cognitive activity and has a negative effect on patients' quality of life (Furneri et al., 2019). Indeed, there is proof that MS -related exhaustion, unemp loyment, and reduced autonomy have a stronger emphasis on health and wellbeing than other causes of impairment (Furneri et al., 2019). Aside from the physical and learning disabilities involved with MS, individuals with MS have a life span of 8 –12 years lo nger than the normal community (Harari et al., 2015). The high cost of injury and premature death, as well as the high economic effects of the disease, make a strong argument for early diagnosis and care optimization of the increasingly effective therapies that are already affordable. Several nations still need patients to try multiple first -line treat ments, such as interferon (IFN) , teriflunomide, or dimethyl fumarate (DMF), before moving on to therapies of higher eff ectiveness, such as fingolimod (Arrambi de et al., 2018). However, there is mounting compelling evidence action following diagnosis, as well as early care optimization in the case of a poor reaction to initial treatment (Fig. 1), are crucial to ensuring a successful result and mitigating the inc remental burden of MS on patients, their communities, and community as a whole (Ziemssen et al., 2015). 4 LONGITUDINAL EVALUATION OF DTI (MRI) FOR RRMS MANAGING Fig 1: (Ziemssen et al., 2015) The trick to having the best results from MS is to maintain track of the disease's activity. However, due to the disease's variability and the sophistication of the fundamental biochemical processes, this may be difficult. Inflammatory response and increme ntal neuroaxonal injury are two main hallmarks of MS pathology (Didonna et al., 2015). Inflammatory is rarely attributed to the onset of subacute clinical symptoms, as well as focal abnormalities on magnetic resonance imaging (MRI) that demonstrate tempora ry penetrability of the blood –brain barrier, as evidenced by data augmentation at acute inflammation sites. Axonal degeneration and neuron death, on the other hand, are linked to long -term impairment and MRI signs of brain or spinal cord atrophy (Fig. 2) (Ziemssen et al., 2016). 5 LONGITUDINAL EVALUATION OF DTI (MRI) FOR RRMS MANAGING FIG 2: (Ziemssen et al., 2015) Axonal transection is a common pathological characteristic of acute MS lesions, and the frequency of neuronal disruption is linked to the severity of the inflammation (Singh et al., 2017). Important ly, such harm may occur early in the course of MS. It may, however, be obscured by processes that compensate for functional failure, such as recruitment of other neuronal pathways or cortical remodelling; therefore, incremental disruption can go unnoticed before it is too late for an intervention to be advantageous (Gass et al., 2015). The equilibrium between degenerative and reparative mechanisms changes as the condition advances, culminating in irreversible neuroaxonal degeneration and growing impairment (Fig. 3). 6 LONGITUDINAL EVALUATION OF DTI (MRI) FOR RRMS MANAGING FIG 3: (Gass et al., 2015) As a result, clinical disease control in MS can consist of three components: Withdrawal symptoms, impairment, and responsiveness are both indicators of disease development (Fig. 4). This obvious lack of association b etween traditional MRI measures and clinical impairment may, instead, be attributed to the poor specificity to clinical disability measures used in normal clinical practise. The commonly used Extended Impairment Status Scale (EDSS), for example, tests the degree of harm already performed but does little about the underlying neurodegenerative and reparative mechanisms. 7 LONGITUDINAL EVALUATION OF DTI (MRI) FOR RRMS MANAGING FIG 4 : (Ziemssen et al., 2015) Other MRI techniques, such as proton magnetic resonance spectroscopy (MRS), diffusion -tensor imaging (DTI) and magnetization transfer (MTR), provide more reliable and better measures with greater pathological susceptibility for disease hallmarks including demyelination and remyelination (MTR, DTI), or axonal degeneration (MRS) (MRS, DTI). In contrast to concent rated MRI lesions, MRI tests of more generalized brain atrophy have gained prominence as a potential predictor of MS -related neuro -axonal damage that could potentially be used to monitor patient outcomes (Wattjes et al., 2015). Brain atrophy is a typical s ymptom of MS, starting in the early stages and continuing over the disease's path (De Stefano et al., 2016). Brain atrophy develops at a pace of 0.5 –1.0 percent per year in individuals with MS, opposed to 0.2 – 0.4 percent in safe people, but it can be remem bered that whether atrophy advances in a longitudinal manner in particular patients remains uncertain. Differences in brain volume in MS may indicate a variety of pathophysiological pathways, such as inflammatory oedema, neuronal or axonal destruction, de - and remyelination, and glial cell number and relative density (Oh et 8 LONGITUDINAL EVALUATION OF DTI (MRI) FOR RRMS MANAGING al., 2019). DMTs currently on the market target numerous facets of the dysregulated immune system, and their primary advantage comes from their anti -inflammatory properties. As a result, the presence of chronic inflammation during therapy implies a bad treatment response. There is some proof that the incidence of recurrent illness during the first one to two years of treatment is associated to bad outcomes (Freedman et al., 2020). Accordi ng to current recommendations, the incidence of two or more lesions (fresh Gd -enhancing lesions or an accumulation of new T2 lesions per year) may necessitate a change in therapy. Newer treatments will produce a slightly greater reduction in certain correl ated with disease growth, as demonstrated by observational studies of fingolimod versus intramuscular IFN -1a, DMF versus glatiramer acetate (post -hoc analysis) (Freedman et al., 2020). The results of switching therapies in the long run are yet to be calcul ated. Routine monitoring MRI can be beneficial, particularly in the first several years of therapy, to enable for early detection of continuing disease behaviour and the use of a different treatment when it is more successful. ROLE PLAYED BY DIFFUSION TENS OR IMAGING (DTI) (MRI) in RRMS : Diffusion tensor imaging (DTI) has been shown to be a useful tool for determining the pathological characteristics of T2 -visible lesions. Enhanced MD and declined FA are more common in lesions than in the NAWM, but their val ues are highly variable, implying differing degrees of tissue loss within MS lesions (Vavasour et al., 2018). The most severe MD abnormalities have been found to be non -enhancing T1 hypointense lesions, which represent areas of permanent tissue disturbance , gliosis, and neural tube, and hence loss of health inequaliti es to water diffusion (Fig. 5) (Sommer et al., 2018). 9 LONGITUDINAL EVALUATION OF DTI (MRI) FOR RRMS MANAGING FIG: 5 selected axial and sagittal diffusion tensor maps of a RRMS patient (Sommer et al., 2018). Nevertheless, by evaluating Gd -enhancing vs. non -enhancing lesions, researchers have come up with conflicting results: one study finds that Gd -enhancing lesions have elevated MD values, although another found no significant difference between the two forms of lesions (Abdoli et al., 20 16). This disparity may be attributed to methodological problems or the existence of disruptive and reparative mechanisms at the same time. A prospective analysis of Gd -enhancing lesions that was tracked for 1 to 3 months observed that MD values were eleva ted in all lesions at variance, but only a subset of them tended to improve at follow -up. Increased MD values were also linked to a higher degree of T1 -hypopointensity (Abdoli et al., 2016). This means that certain tissue defects in acute lesions are due t o neurodegenerative disorders and hence irreversible, while 10 LONGITUDINAL EVALUATION OF DTI (MRI) FOR RRMS MANAGING others are linked to edoema, demyelination, and remyelination and furthermore transient. In comparison to MD, FA is often lower in Gd -enhancing lesions, especially ring -enhancing lesions, than in non -enhancing lesions, suggesting demyelination, axonal injury, and inflammatory cell aggregation (Abdoli et al., 2016). Surprisingly, a new analysis showed that MS patients' cortical lesions had higher MD and FA values than stable controls' cortical GM (S teenwijk et al., 2015). The enhanced anisotropy in cortical lesions contrasts with the decrease in FA in WM lesions, suggesting that decreased dendritic arborization, which is characteristic of cortical lesions, can enhance consistency and, as a result, di ffusion anisotropy. Standard MRI is very susceptible to macroscopic lesions, but it is not sensitive to the ‘hidden' microscopic pathology involving NAWM and NAGM. Several experiments, on the other hand, have identified anomalies in diffusion MRI parameter s outside of T2 lesions in MS patients' NAWM and NAGM, improving the effectiveness of MS pathophysiology (Yaldizli et al., 2016). As a result, new lesions can be accompanied by incremental, but subtle, tissue anomalies that are outside the management of st andard MRI. A milder rise in ADC was also observed in NAWM regions contralateral to the newly appeared lesions, promoting the hypothesis that NAWM anomalies are triggered by secondary degeneration of axons transected within lesions (Yaldizli et al., 2016 ). Diffusion defects of normal -appearing brain tissue can be triggered by astrocytic hyperplasia, patchy edoema, perivascular invasion, demyelination, and axonal loss (Yaldizli et al., 2016). Furthermore, many DTI experiments have shown that NAWM damage beco mes more prominent with growing disease length and clinical impairment, meaning that DTI is likely to be susceptible to more serious clinical manifestations (Rocca et al., 2016). Since MS is a diffuse and prevalent CNS disease, histogram review may be used to analyse DTI modifications on a global level. MS patients have a slightly higher average MD, a lower average FA, and a lower 11 LONGITUDINAL EVALUATION OF DTI (MRI) FOR RRMS MANAGING histogram peak heig ht MD than stable monitors. These DTI variations are slightly more pronounced in SPMS patients than in RR -MS patients, implying that DTI should be used to control advanced phases of the disease (Rocca et al., 2016). Several DTI research have looked at patients with primary -progressive (PP) MS to try to figure out what causes this form of MS, which is marked by at ypical MRI features such as little lesions and no Gadolinium enhancement (De Santis et al., 2017). While these patients' NAWM and NAGM had MD and FA anomalies, no substantial link was observed between lesion load and DTI anomalies in standard tissue, imply ing that microscopic diffuse brain alterations in these patients are unrelated to T2 -visible lesions (Rocca et al., 2016). Histogram -derived DTI metrics can be particularly useful for evaluating disease severity and clinical presentation since they allow f or the assessment of morbidity and mortality, specifically macroscopic abnormalities and microscopic harm in NAWM and NAGM. In other research, however, measuring regional harm with DTI was found to be more sensitive than knowing about the imagery implicati ons of MS clinical status using a global tool. According to a recent research that used a voxel -based approach, patients with RR and benign MS differ in elevation propagation of WM disturbance rather than the worldwide scale of brain alterations. The fact that the frontal lobe WM has a smaller function in benign MS could be linked to the better clinical outcome. NAGM MD is more popular in people with SPMS and PPMS than in people with RRMS, and in people with SPMS and PPMS than in people with RRMS (Rocca et al., 2016). The formation of cortical lesions that are sometimes undetectable on T2 -weighted images, as well as the retrogressive calcification of cortical neurons induced by WM axon injury, can activate NAGM abnormalities. 12 LONGITUDINAL EVALUATION OF DTI (MRI) FOR RRMS MANAGING Monitoring of MS and CORRELATION S IN BETWEEN DIFFUSION TENSOR IMAGING (DTI) AND WITH CLINICAL PARAMETERS: Recent studies have shown a connection between DTI results and MS clinical symptoms and injury, suggesting that DTI may be used as a measure of functional presentation and a method for tracking medication adherence in clinical trials. The diffusion properties of T2 lesions and GM have been shown to have the greatest correlation to clinical impairment (Gratsias et al., 2015). Although one research found no connection between DTI metric s and the existence and intensity of fatigue in MS patients, other authors have presented that DTI -derived indicators could play a role in explaining cognitive impairment's correlates (Gratsias et al., 2015). The disorder takes a relapsing –remitting route (RRMS) in the majority of MS cases, with acute symptomatic relapses accompanied by cycles of variable rehabilitation. More than half of patients with RRMS can experience progressive disabilities after 15 years if they do not undergo care (Hemond & Bakshi, 2018). Natural history experiments have shed light on the factors that influence impairment development in early MS. One such study discovered a connection between early -stage MS relapses and long -term impairment, which was mainly motivated by an increased risk of RRMS and, to a lesser degree, by the impact of repeated relapses on the pace of progression (Bsteh et al., 2016). Another research discovered that age at start of MS, residual deficiencies following a first relapse, and the amount of relapses in t he first two years were both indicative of the period it took to reach an Impairment Status Score (DSS) of 3 (moderate disability), although not of the time it took to reach DSS 6 (requiring help to walk) (Bsteh et al., 2016). These results, according to t he scientists, are compatible with guidelines of progressive impairment, in which the first stage is linked to specific inflammation that can be treated, and the 13 LONGITUDINAL EVALUATION OF DTI (MRI) FOR RRMS MANAGING stage two is unrelated to existing inflammation and may be linked to diffuse neurodegeneration (Hemond & Bakshi, 2018). Conclusion: The launch of increasingly promising therapies for RRMS patients, such as fingolimod and DMF -Tecfidera, has greatly improved therapeutic choices. Around the same period, care selection has taken on different significan ce for a variety of factors. There is clear evidence that in patients with early MS, there is a short time span to treat successfully, and that action within this time tends to be crucial for obtaining favourable long -term results. Furthermore, a novel tre atment approach has emerged: treating to obtain no signs of pathological development, which could include brain tissue preservation in addition to the conventional endpoints of psychiatric relapses and MRI inflammatory measures. Pertinently, treating to go al necessitates constant surveillance of disease occurrence in order to enable timely therapeutic improvements in the event of treatment failure. Identification and timely reaction to suboptimal response or treatment failure are needed for successful inter vention within the window of opportunity. The studies examined here show that DTI -derived measures in the NAWM and NAGM are more relevant to disease pathophysiological mechanisms and vulnerable to diffuse microscopic damage. DTI - derived tests associate wit h physical weakness and cognitive dysfunction in clinical terms, and the degree of DTI modifications in normal -appearing tissue can have predictive significance for potential clinical results. Consequently, DTI -derived tests have the potential to be used i n MS clinical trials to evaluate medication adherence. However, broad, prospective studies are needed to validate DTI's level of accuracy in identifying MS -related mitochondrial dysfunction. Future advancements in retrieval and post -processing techniques, as well as therapeutic use at higher 14 LONGITUDINAL EVALUATION OF DTI (MRI) FOR RRMS MANAGING field strengths, could result in increased spatial resolution, accuracy, and pathological sensitivity of diffusion imaging steps. 15 LONGITUDINAL EVALUATION OF DTI (MRI) FOR RRMS MANAGING References: Abdoli, M., Chakraborty, S., MacLean, H. J., & Freedman, M. S. (2016). The evaluation of MRI diffusion values of active demyelinating lesions in multiple sclerosis. Multiple sclerosis and related disorders , 10 , 97 -102. https://www.sciencedirect.com/science/article/pii/S2211034816301699 Arrambide, G., Tintore, M., Espejo, C., Auger, C., Castillo, M., Río, J., ... & Montalban, X. (2018). The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. Brain , 141 (4), 1075 -1084. https://academic.oup.com/brain/article - abstract/141/4/1075/4866204 Bsteh, G., Ehling, R., Lutterotti, A., Hegen, H., Di Pauli, F., Auer, M., ... & Berger, T. (2016). Long term clinical prognostic factors in relapsing -remitting multiple sclerosis: insights from a 10 -year observational study. PloS one , 11 (7), e0158978. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0158978 Burt, R. K., Balab anov, R., Burman, J., Sharrack, B., Snowden, J. A., Oliveira, M. C., ... & Helenowski, I. B. (2019). Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease -modifying therapy on disease progression in patients with relapsing -remitting multiple sclerosis: a randomized clinical trial. Jama , 321 (2), 165 -174. https://jamanetwork.com/journals/jama/article -abstract/2720728 De Santis, S., Granberg, T., Ou ellette, R., Treaba, C. A., Fan, Q., Herranz, E., ... & Toschi, N. (2017, July). Early axonal damage in normal appearing white matter in multiple sclerosis: Novel insights from multi -shell diffusion MRI. In 2017 39th Annual International 16 LONGITUDINAL EVALUATION OF DTI (MRI) FOR RRMS MANAGING Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) (pp. 3024 -3027). IEEE. https://ieeexplore.ieee.org/abstract/document/8037494/ De Stefano, N., Stromillo, M. L., Giorgio, A., Bart olozzi, M. L., Battaglini, M., Baldini, M., ... & Sormani, M. P. (2016). Establishing pathological cut -offs of brain atrophy rates in multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry , 87 (1), 93 -99. https://jnnp.bmj.com/content/87/1/93.short Didonna, A., Isobe, N., Caillier, S. J., Li, K. H., Burlingame, A. L., Hauser, S. L., ... & Oksenberg, J. R. (2015). A non -synonymous single -nucleotide poly morphism associated with multiple sclerosis risk affects the EVI5 interactome. Human molecular genetics , 24 (24), 7151 -7158. https://academic.oup.com/hmg/article - abstract/24/24 /7151/2384912 Dolati, S., Marofi, F., Babaloo, Z., Aghebati -Maleki, L., Roshangar, L., Ahmadi, M., ... & Yousefi, M. (2018). Dysregulated network of miRNAs involved in the pathogenesis of multiple sclerosis. Biomedicine & Pharmacotherapy , 104 , 280 -290. https://www.sciencedirect.com/science/article/pii/S0753332218322364 Freedman, M. S., Devonshire, V., Duquette, P., Giacomini, P. S., Giuliani, F., Levin, M. C., ... & Yeh, E. A. (2020). Treatment optimization in multiple sclerosis: Canadian MS Working Group recommendations. Canadian Journal of Neurological Sciences , 47 (4), 437 -455. https://www.cambridge.org/core/journals/canadian -journal -of-neurological - sciences/article/treatment -optimization -in-multiple -sc lerosis -canadian -ms -working -group - recommendations/6F71BA9F915D7AC1228BBB52EF3B8AD7 Furneri, G., Santoni, L., Ricella, C., & Prosperini, L. (2019). Cost -effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing -rem itting 17 LONGITUDINAL EVALUATION OF DTI (MRI) FOR RRMS MANAGING multiple sclerosis in Italy. BMC health services research , 19 (1), 1 -9. https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913 -019 -4264 -1 Gasper ini, C., Prosperini, L., Tintoré, M., Sormani, M. P., Filippi, M., Rio, J., ... & MAGNIMS Study Group. (2019). Unraveling treatment response in multiple sclerosis: a clinical and MRI challenge. Neurology , 92 (4), 180 -192. https://n.neurology.org/content/92/ 4/180.abstract Gass, A., Rocca, M. A., Agosta, F., Ciccarelli, O., Chard, D., Valsasina, P., ... & MAGNIMS Study Group. (2015). MRI monitoring of pathological changes in the spinal cord in patients with multiple sclerosis. The Lancet Neurology , 14 (4), 443 -454. https://www.sciencedirect.com/science/article/pii/S1474442214702947 Göçmen, R. (2018). The Relevance of Neuroimaging Findings to Physical Disability in Multiple Sclerosis. Archives of Neuropsychiatry , 55 (Suppl 1), S31. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278625/ Gratsias, G., Kapsalaki, E., Kogia, S., Dardiotis, E., Tsimourtou, V., Lav das, E., ... & Fezoulidis, I. (2015). A quantitative evaluation of damage in normal appearing white matter in patients with multiple sclerosis using diffusion tensor MR imaging at 3 T. Acta Neurologica Belgica , 115 (2), 111 -116. https://link.springer.com/article/10.1007/s13760 -014 - 0338 -3 Guzel, I., Mungan, S., Oztekin, Z. N., & Ak, F. (2016). Is there an association between the Expanded Disability Status Scale and inflammatory marker s in multiple sclerosis?. Journal of the Chinese Medical Association , 79 (2), 54 -57. https://www.sciencedirect.com/science/article/pii/S1726490115002804 18 LONGITUDINAL EVALUATION OF DTI (MRI) FOR RRMS MANAGING Harari, D., Orr, I., Rotkopf, R., Baranzini, S. E., & Schreiber, G. (2015). A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis. Human molecular gen etics , 24 (11), 3192 -3205. https://academic.oup.com/hmg/article -abstract/24/11/3192/720845 Hemond, C. C., & Bakshi, R. (2018). Magnetic resonance imaging in multiple sclerosis. Cold Spring Harbor perspectives in medicine , 8(5), a028969. http://perspectivesinmedicine.cshlp.org/content/8/5/a028969.short Hynčicová, E., Vyhnálek, M., Kalina, A., Martink ovič, L., Nikolai, T., Lisý, J., ... & Laczó, J. (2017). Cognitive impairment and structural brain changes in patients with clinically isolated syndrome at high risk for multiple sclerosis. Journal of neurology , 264 (3), 482 - 493. https://link.springer.com/article/10.1007/s00415 -016 -8368 -9 Oh, J., Ontaneda, D., Azevedo, C., Klawiter, E. C., Absinta, M., Arnold, D. L., ... & Reich, D. S. (2019). Imaging outcome measures of neuroprotection and repair in MS: a consensus statement from NAIMS. Neurology , 92 (11), 519 -533. https://n.neurology.org/content/92/11/519.abstract Piaggio, N., Schiavi, S., Mar tino, M., Bommarito, G., Inglese, M., & Magioncalda, P. (2018). Exploring mania -associated white matter injury by comparison with multiple sclerosis: a diffusion tensor imaging study. Psychiatry Research: Neuroimaging , 281 , 78 -84. https://www.sciencedirect.com/science/article/pii/S0925492718301999 19 LONGITUDINAL EVALUATION OF DTI (MRI) FOR RRMS MANAGING Radue, E. W., Barkhof, F., Kappos, L., Sprenger, T., Häring, D. A., de Vera, A., ... & Cohen, J. A. (2015). Correlation between b rain volume loss and clinical and MRI outcomes in multiple sclerosis. Neurology , 84 (8), 784 -793. https://n.neurology.org/content/84/8/784.short Rocca, M. A., Comi, G., & Filippi, M. (2017). The role of T1 -weighted derived measures of neurodegeneration for assessing disability progression in multiple sclerosis. Frontiers in neurology , 8, 433. https://www.frontiersi n.org/articles/10.3389/fneur.2017.00433/full Rocca, M. A., Preziosa, P., Mesaros, S., Pagani, E., Dackovic, J., Stosic -Opincal, T., ... & Filippi, M. (2016). Clinically isolated syndrome suggestive of multiple sclerosis: dynamic patterns of gray and white matter changes — a 2 -year MR imaging study. Radiology , 278 (3), 841 -853. https://academic.oup.com/brain/article - abstract/140/11/2814/4259067 Rocca, M. A., Sonkin, M., Copetti, M., Pagani, E., Arnold, D. L., Narayanan, S., ... & Filippi, M. (2016). Diffusion tensor magnetic resonance imaging in very early onset pediatric multiple sclerosis. Multiple Sclerosis Journal , 22 (5), 620 -627. https://journals.sagepub.com/doi/abs/10.1177/1352458515596600 Singh, S., Dallenga, T., Winkler, A., Roemer, S., Maruschak, B., Siebert, H., ... & Stadelmann, C. (2017). Relationship of acute axonal damage, Wallerian degeneration, and clinical disability in multiple sclerosis. Journal of neuroinflammation , 14 (1), 1 -15. https://j neuroinflammation.biomedcentral.com/articles/10.1186/s12974 -017 -0831 -8 Sommer, N. N., Saam, T., Coppenrath, E., Kooijman, H., Kümpfel, T., Patzig, M., ... & Treitl, K. M. (2018). Multiple sclerosis: improved detection of active cerebral lesions with 3 - dime nsional T1 black -blood magnetic resonance imaging compared with conventional 3 - 20 LONGITUDINAL EVALUATION OF DTI (MRI) FOR RRMS MANAGING dimensional T1 GRE imaging. Investigative radiology , 53 (1), 13 -19. https://journals.lww.com/investigativeradiology/Fulltext/2018/01000/Multiple_Sclerosis__Improved _Detection_of_Active.3.aspx Steenwijk, M. D., Daams, M., Pouwels, P. J., J. Balk, L., Tewarie, P. K., Geurts, J. J., ... & Vrenken , H. (2015). Unraveling the relationship between regional gray matter atrophy and pathology in connected white matter tracts in long ‐standing multiple sclerosis. Human brain mapping , 36 (5), 1796 -1807. https://onlinelibrary.wiley.com/doi/abs/10.1002/hbm.22738 Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., ... & Cohen, J. A. (2018). Diagnosis of multiple sclerosis: 2017 revisions of the McDonald cri teria. The Lancet Neurology , 17 (2), 162 -173. https://www.sciencedirect.com/science/article/pii/S1474442217304702 Vanbellingen, T., & Kamm, C. P. (2016, April). Neurorehabil itation topics in patients with multiple sclerosis: from outcome measurements to rehabilitation interventions. In Seminars in neurology (Vol. 36, No. 02, pp. 196 -202). Thieme Medical Publishers. https://www.thieme -connect.com/products/ejournals/abstract/10.1055/s -0036 -1579694 Vavasour, I. M., Huijskens, S. C., Li, D. K., Traboulsee, A. L., Mädler, B., K olind, S. H., ... & Laule, C. (2018). Global loss of myelin water over 5 years in multiple sclerosis normal - appearing white matter. Multiple Sclerosis Journal , 24 (12), 1557 -1568. https://journals.sagepub.com/doi/abs/10.1177/1352458517723717 Wattjes, M. P., Rovira, À., Miller, D., Yousry, T. A., Sormani, M. P., De Stefano, N., ... & MAGNIMS study group. (2015). Evidence -based guidelines: MAGNIMS consensus guidelines on the use of M RI in multiple sclerosis — establishing disease prognosis and 21 LONGITUDINAL EVALUATION OF DTI (MRI) FOR RRMS MANAGING monitoring patients. Nature Reviews Neurology , 11 (10), 597. https://www.nature.com/articles/nrneurol.2015.157.pdf? origin=ppub Yaldizli, Ö., Pardini, M., Sethi, V., Muhlert, N., Liu, Z., Tozer, D. J., ... & Chard, D. T. (2016). Characteristics of lesional and extra -lesional cortical grey matter in relapsing –remitting and secondary progressive multiple sclerosis: a magn etisation transfer and diffusion tensor imaging study. Multiple Sclerosis Journal , 22 (2), 150 -159. https://journals.sagepub.com/doi/abs/10.1177/1352458515586085 Zhang, Y., Gauthi er, S. A., Gupta, A., Tu, L., Comunale, J., Chiang, G. Y., ... & Wang, Y. (2016). Magnetic susceptibility from quantitative susceptibility mapping can differentiate new enhancing from nonenhancing multiple sclerosis lesions without gadolinium injection. Am erican Journal of Neuroradiology , 37 (10), 1794 -1799. http://www.ajnr.org/content/37/10/1794.short Ziemssen, T., De Stefano, N., Sormani, M. P., Van Wijmeersch, B., Wiendl, H., & Kieseier, B. C. ( 2015). Optimizing therapy early in multiple sclerosis: an evidence -based view. Multiple sclerosis and related disorders , 4(5), 460 -469. https://www.sciencedirect.com/scienc e/article/pii/S2211034815001066 Ziemssen, T., Derfuss, T., de Stefano, N., Giovannoni, G., Palavra, F., Tomic, D., ... & Schippling, S. (2016). Optimizing treatment success in multiple sclerosis. Journal of neurology , 263 (6), 1053 -1065. doi.org/10.1007/s00415 -015 -7986 -y